Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress. We here show that glutamyl-prolyl-tRNA synthetase (GluProRS) inhibition constitutes a novel therapeutic target. Genomic data suggest...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
格式: | Journal article |
語言: | English |
出版: |
Springer Nature
2023
|